Use of phenytoin and carbamazepine in treatment of epilepsy.
This article reviews the clinical pharmacology of carbamazepine and phenytoin, widely regarded as the drugs of choice for partial and secondary generalized seizures.
D000741:Anemia, Aplastic / Q000139:chemically induced; D002220:Carbamazepine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002524:Cerebellar Ataxia / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D003072:Cognition Disorders / Q000139:chemically induced; D003875:Drug Eruptions / Q000209:etiology; D004347:Drug Interactions; D004827:Epilepsy / Q000188:drug therapy*; D005885:Gingival Hyperplasia / Q000139:chemically induced; D006207:Half-Life; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000139:chemically induced; D010672:Phenytoin / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D014202:Tremor / Q000139:chemically induced
D002220:Carbamazepine; D010672:Phenytoin